Clinical Trials
43 trialsTARSARC
Institut Bergonié
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
M.D. Anderson Cancer Center
GEMMK
Royal Marsden NHS Foundation Trust
Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities
Wake Forest University Health Sciences
MAGNATE-S
Shanghai 6th People's Hospital
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Washington University School of Medicine
SeliSarc
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma Inc.
BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Emory University
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Sarcoma Oncology Research Center, LLC
Dendritic Cell Vaccine for Children and Adults With Sarcoma
University of Miami
SeliSarc
Grupo Espanol de Investigacion en Sarcomas
Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma
University of Iowa
Gemcitabine With Ascorbate Including Adolescents
University of Iowa
NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma
Swiss Cancer Institute
GemTax
University of Pittsburgh
A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma
Yonsei University
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Massachusetts General Hospital
Gemcitabine Plus Ascorbate for Sarcoma in Adults
University of Iowa
Alimta Plus Gemcitabine for Advanced Sarcoma
Columbia University
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
Medical University of South Carolina
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
University of Iowa
Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)
Western Regional Medical Center
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
UNICANCER
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
University of Vermont
PP-Gemcitabine & External Beam Radiation-Sarcomas
M.D. Anderson Cancer Center
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Memorial Sloan Kettering Cancer Center
Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma
Grupo Espanol de Investigacion en Sarcomas
Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
New Mexico Cancer Research Alliance
STS
National Health Research Institutes, Taiwan
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Sarcoma Alliance for Research through Collaboration
Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy
Asan Medical Center
Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center